Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-447-3 | CAS number: 99607-70-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 20 July 1987 to 14 November 1987
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
- Objective of study:
- metabolism
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
Test material
- Reference substance name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- EC Number:
- 619-447-3
- Cas Number:
- 99607-70-2
- Molecular formula:
- C18H22ClNO3
- IUPAC Name:
- heptan-2-yl [(5-chloroquinolin-8-yl)oxy]acetate
- Details on test material:
- - Name of test material (as cited in study report): CGA185072 (company code)
See details given in attached word file
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- [3-14C] quinoline-CGA 185072
Test animals
- Species:
- rat
- Strain:
- other: Tif RAIf (SPF), Sprague-Dawley derived
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 6-8 weeks
- Weight at study initiation: circa 200g
- Individual metabolism cages: yes
- Acclimation period: 4 days
IN-LIFE DATES: From: 20 July 1987 To: 14 November 1987
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: PEG200/ethanol/water (4/3/2 v/v)
- Details on exposure:
- The test material was dissolved in PEG200/ethanol/water (4/3/2 v/v) yielding solutions of 11.42 mg/ml (males) and 11.64 mg/ml (females) respectively. A single dose of 0.9 ml was administered by gastric intubation. The stability of the dosing emulsion was checked by TLC at the time of dosing. This dose was equivalent to about 50 mg/kg bw.
A total of 5 male and 5 female rats were treated. Urine and faeces were collected at 24 hour intervals for three days. At sacrifice, kidneys, liver and the residual carcass were sampled.
See details of exposure given in tables below. - Duration and frequency of treatment / exposure:
- Single
Doses / concentrations
- Dose / conc.:
- 50 mg/kg bw/day
- No. of animals per sex per dose / concentration:
- A total of 5 male and 5 female rats were treated. Urine and faeces were collected at 24 hour intervals for three days. At sacrifice, kidneys, liver and the residual carcass were sampled.
- Control animals:
- no
- Details on study design:
- The test material was dissolved in PEG200/ethanol/water (4/3/2 v/v) yielding solutions of 11.42 mg/ml (males) and 11.64 mg/ml (females) respectively. A single dose of 0.9 ml was administered by gastric intubation. The stability of the dosing emulsion was checked by TLC at the time of dosing. This dose was equivalent to about 50 mg/kg bw
Five male andfive females were dosed at 50 or 52 mg/kg bw the dose of labelled material (KBq/rat) was 7610 or 7470 respectively.
The pattern of radioactivity was determined using TLC methods. Separation and purification of samples was done by LC, HPLC and HVE to separate and purify individual metabolites.
The main metabolite was identified by co-chromatography with reference substances and finally, the structure was confirmed by NMR and mass spectroscopy.
Results and discussion
Main ADME resultsopen allclose all
- Type:
- distribution
- Results:
- Tissue residues were low; liver, kidney and carcass contained <0.3% of dose after 3 days.
- Type:
- excretion
- Results:
- 38.9 and 34.5% in urine and 59.4 and 59.7% in males and females respectively.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Urine and faeces contained only one major metabolite fraction accounting for around 95% of the recovered radioactivity. No significant differences were observed between males and females. The structure was identified as the acid residue of cloquintocet-mexyl after cleavage of the ester bond (see attached metabolic pathway).
Any other information on results incl. tables
Balance of radioactivity in male rats after oral gavage of 14 C-CGA 185072 (Radioactivity in % of the administered dose)
Males |
Females |
|
Dose mg/kg bw |
50 mg/kg bw |
52 mg/kg bw |
Urine Subtotal |
1.1 0.2 40.2 |
34.5 0.9 0.2 35.6 |
Faeces 0 - 24 hrs Subtotal |
59.4 2.8 0.1 62.3 |
59.7 2.0 0.2 61.9 |
Tissue Residues |
0.03 0.01 0.13 0.16 |
0.01 0.01 0.25 0.26 |
Total Recovery |
102.7 |
97.8 |
The metabolism of [3-14C] quinoline-CGA 185072 in the rat after oral administration of a single dose of 50 mg/kg bw revealed only one major metabolite CGA 153433, which accounted for around 95% of the recovered radioactivity in urine and faeces. No significant differences were observed between males and females.
Applicant's summary and conclusion
- Conclusions:
- The metabolism of [3-14C] quinoline labelled substance in the rat after oral administration of a single dose of 50 mg/kg bw revealed only one major metabolite, which accounted for 95% of the recovered radioactivity in urine and faeces. No significant differences were observed between males and females.
- Executive summary:
The metabolism of cloquintocet-mexyl in the rat, following a single oral dose of 50 mg/kg bw/day of [3-14C] quinoline-labelled substance, was studied under GLP to EPA OPP methods. The metabolites in urine, faeces and bile were separated and the main metabolites were identified by co-chromatography with reference substances. In all samples the metabolite profile was dominated by one single metabolite which was identified by co-chromatography as the acid residue of cloquintocet-mexyl after cleavage of the ester bond. The major metabolite accounted for 95% of the recovered radioactivity. Few other metabolite fractions were detected, none of which exceeded 0.5% of the administered dose. The metabolite pattern was independent of sex or pretreatment.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.